Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.65 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17179173 | 0.82 | PARP1 (0.54) | CCR1BACE1ARLMNASMN1; SMN2 | |
| SCHEMBL28722027 | 0.82 | CCR1 (0.63) | CCR1BACE1ARLMNASMN1; SMN2 | |
| SCHEMBL1258482 | 0.80 | CCR1 (1.00) | CCR1LMNASMN1; SMN2PARP1RAB9A | |
| SCHEMBL201143 | 0.78 | CCR1 (0.63) | CCR1BACE1ARLMNASMN1; SMN2 | |
| SCHEMBL29518341 | 0.78 | CCR1 (0.63) | CCR1BACE1ARLMNASMN1; SMN2 | |
| SCHEMBL9684142 | 0.78 | CCR1 (0.63) | CCR1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL2707252 | 0.78 | CCR1 (0.63) | CCR1ARLMNAPARP1MAPT | |
| SCHEMBL6196701 | 0.78 | CCR1 (0.63) | CCR1ARLMNASMN1; SMN2PARP1 | |
| SCHEMBL29496015 | 0.78 | BACE1 (0.49) | CCR1BACE1ARLMNASMN1; SMN2 | |
| SCHEMBL1579557 | 0.78 | BACE1 (0.49) | CCR1BACE1ARLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041597-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| EP-3902533-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020139916-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020139916-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-2176277-B1 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | UNIV GEORGIA STATE RES FOUND (US) | 2016-02-24 | — | — | EP | disclosed |
| US-9096856-B2 | Nucleotides and aptamers containing boronic acid groups having biased binding to glycosylated proteins, and uses thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130184160-A1 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| EP-1558578-B1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-03-13 | — | — | EP | disclosed |
| EP-2357173-A1 | New alkyne compounds with MCH-antagonistic activity and medicaments containing them | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110144187-A1 | APTAMER INHIBITION OF THROMBUS FORMATION | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION | 2011-06-16 | — | — | US | disclosed |
| EP-2176277-A2 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | Georgia State University Research Foundation, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2010019847-A2 | APTAMER INHIBITION OF THROMBUS FORMATION | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2009012363-A2 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20070274922-A1 | Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | disclosed |
| US-20070274922-A1 | Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | disclosed |
| US-20070274922-A1 | Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | disclosed |
| EP-1558578-A1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005024416-A1 | WATER SOLUBLE BORONIC ACID FLUORESCENT REPORTER COMPOUNDS AND METHODS OF USE THEREOF | WANG BINGHE (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004039780-A1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003010137-A1 | PREPARATION OF SULFONYL QUINOLINE | MERCK & CO., INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184160-A1 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | TENT4A, PABPC4, NUDT21 | CCR1 2797/4885BACE1 3253/4885AR 3992/4885 |
| US-20070274922-A1 | Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof | GUSB, BLVRB, BCL6 | CCR1 2402/4885BACE1 3510/4885AR 2834/4885 |
| US-20110144187-A1 | APTAMER INHIBITION OF THROMBUS FORMATION | FGB, F13B, GP6 | CCR1 4146/4885BACE1 3428/4885AR 3507/4885 |
| US-20220041597-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | MCL1, HSPA9, USP10 | CCR1 4756/4885BACE1 2051/4885AR 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.